PD-L1 testing now available for free!
Under the Early Access to Medicine Scheme, Viapath is able to offer PD-L1 testing for the Merck, Sharp and Dohme (MSD) drug KEYTRUDA when it is being used for the treatment of non small cell lung cancer.
Initially the PD-L1 test is being funded by MSD who will pay for all tests referred to Viapath. This means that, until approval from NICE, this test will be free to the originating hospital.
PD-L1 is an immune-related biomarker that is expressed on tumour cells in various tumour types, including Non Small Cell Lung Cancer (NSCLC). Assessing PD-L1 expression in squamous and non-squamous NSCLC may contribute to a better understanding of a patient's tumour and KEYTRUDA is indicated for the treatment of patients with metastatic NSCLC whose tumours express PD-L1.
PD-L1 expression helps identify patients that are most likely to benefit from KEYTRUDA